{
    "id": 10286,
    "name": "prostate carcinoma",
    "source": "DOID",
    "definition": "A prostate cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. [url:http\\://en.wikipedia.org/wiki/Carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:10286",
    "evidence": [
        {
            "id": 2511,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BEZ235 resulted in a decrease in prostate cancer progenitor cells in culture and reduced tumor growth in prostate carcinoma xenograft models (PMID: 21138868).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3195,
                    "pubMedId": 21138868,
                    "title": "Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21138868"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3669,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI2536 and Metformin worked synergistically to induce apoptosis and inhibit growth of PLK1-over expressing prostate cancer cells with wild-type TP53 in cell culture and in PDX models (PMID: 25505174).",
            "molecularProfile": {
                "id": 14280,
                "profileName": "PLK1 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 3223,
                "therapyName": "BI2536 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3947,
                    "pubMedId": 25505174,
                    "title": "Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3670,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased expression of Tp53 in Plk1-over expressing prostate carcinoma cell lines resulted in decreased response to growth inhibition by the combination of BI2536 and Metformin in culture (PMID: 25505174).",
            "molecularProfile": {
                "id": 14282,
                "profileName": "PLK1 over exp TP53 dec exp"
            },
            "therapy": {
                "id": 3223,
                "therapyName": "BI2536 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3947,
                    "pubMedId": 25505174,
                    "title": "Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4358,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911).",
            "molecularProfile": {
                "id": 17821,
                "profileName": "RB1 mut TP53 mut"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5080,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) treatment resulted in minor inhibition of tumor growth in xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5081,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 treatment resulted in minor inhibition of tumor growth in xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 992,
                "therapyName": "AZD8186",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5083,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and Alpelisib (BYL719) combination treatment resulted in inhibition of tumor growth in xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 3749,
                "therapyName": "Alpelisib + AZD8186",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5084,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186, Alpelisib (BYL719) and Xtandi (enzalutamide) combination treatment resulted in tumor regression in xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 3750,
                "therapyName": "Alpelisib + AZD8186 + Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5086,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XTANDI (enzalutamide) treatment resulted in tumor growth inhibition in cell line xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5087,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Alpelisib (BYL719) and Xtandi (enzalutamide) resulted in tumor growth inhibition in xenograft models of an AR-dependent, PTEN-mutant human prostate cancer cell line (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 3751,
                "therapyName": "Alpelisib + Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5088,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and Xtandi (enzalutamide) combination treatment resulted in complete inhibition of tumor growth in xenograft models of AR-dependent prostate cancer cells harboring PTEN mutations (PMID: 25544636).",
            "molecularProfile": {
                "id": 20265,
                "profileName": "AR pos PTEN mut"
            },
            "therapy": {
                "id": 3752,
                "therapyName": "AZD8186 + Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7772,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a precliinical study, PTEN deficient prostate carcinoma cells demonstrated reduced response to SAR260301 in cell culture and in cell line xenograft models (PMID: 27196754).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 1052,
                "therapyName": "SAR260301",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6491,
                    "pubMedId": 27196754,
                    "title": "Concomitant Inhibition of PI3K\u03b2 and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K\u03b2-Selective Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196754"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01385228",
            "title": "Pazopanib, Docetaxel, Prednisone Prostate",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2042,
                    "therapyName": "Docetaxel + Pazopanib + Pegfilgrastim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01391143",
            "title": "Safety Study of MGA271 in Refractory Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2863,
                    "therapyName": "MGA271",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01561482",
            "title": "Study of Metformin With Simvastatin for Men With Prostate Carcinoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1829,
                    "therapyName": "Metformin + Simvastatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02113657",
            "title": "T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02234115",
            "title": "Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02516553",
            "title": "BI 894999 First in Human Dose Finding Study in Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5884,
                    "therapyName": "BI 894999",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02565901",
            "title": "Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3111,
                    "therapyName": "Carboplatin + Docetaxel + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02723955",
            "title": "Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4409,
                    "therapyName": "GSK3359609",
                    "synonyms": null
                },
                {
                    "id": 4410,
                    "therapyName": "GSK3359609 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02952534",
            "title": "A Study of Rucaparib in Patients With MetA Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 906,
                    "therapyName": "Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02975934",
            "title": "A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 906,
                    "therapyName": "Rucaparib",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03261999",
            "title": "Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03263650",
            "title": "Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3844,
                    "therapyName": "Cabazitaxel + Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03837353",
            "title": "A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6244,
                    "therapyName": "DKN-01",
                    "synonyms": null
                },
                {
                    "id": 8989,
                    "therapyName": "DKN-01 + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04179396",
            "title": "Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (RAMP)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9243,
                    "therapyName": "Enzalutamide + Rucaparib",
                    "synonyms": null
                },
                {
                    "id": 9244,
                    "therapyName": "Abiraterone + Rucaparib",
                    "synonyms": null
                }
            ]
        }
    ]
}